BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary
February 23 2021 - 7:00AM
BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq:
BTAI), a clinical-stage biopharmaceutical company utilizing
artificial intelligence approaches to develop transformative
medicines in neuroscience and immuno-oncology, today announced the
appointment of Javier Rodriguez as Senior Vice President, Chief
Legal Officer and Corporate Secretary, effective immediately. Mr.
Rodriguez will report to Chief Executive Officer, Vimal Mehta and
joins BioXcel with 20 years of extensive strategic and legal
experience within the biopharmaceutical industry.
“We are pleased to welcome Javier to BioXcel at
this important time in our Company’s growth,” said Dr. Mehta. “As
we look to transition to a commercial neuroscience-focused company,
Javier’s proven track record and broad legal expertise within the
life sciences – spanning commercial, clinical and intellectual
property activities – makes him an invaluable addition to our
management team. We look forward to leveraging his vast knowledge
as we advance on our path to commercialization.”
Prior to joining BioXcel, Mr. Rodriguez served
as Chief Legal Officer at Indivior PLC (LSE: INDV), a publicly
traded pharmaceutical company. During his tenure, he oversaw all
legal affairs, data privacy compliance and corporate governance
matters for the company, which has operations in over 40 countries.
Prior to joining Indivior, he held roles of increasing
responsibility at Reckitt Benckiser LLC, Bayer Healthcare
Pharmaceuticals, Inc. and Berlex, Inc. Mr. Rodriguez began his
legal career as a litigation associate at Thelen Reid & Priest,
LLP in New York City. He holds a bachelor’s degree from Rutgers
University, a Master of Science degree from the University of
Michigan and a Juris Doctor from the University of
Pennsylvania.
“I am thrilled to be joining BioXcel at this
exciting time in the Company’s life cycle. In just a few years, the
Company has been able to advance its first candidate to the cusp of
an NDA filing with the FDA, leveraging its powerful AI platform to
identify valuable, proprietary assets for treating underserved
neuropsychiatric disorders,” commented Javier Rodriguez. “With my
prior experience in the industry, including direct experience with
sublingually administered treatments that utilize proprietary
technology, I look forward to providing strategic counsel and
contributing to the Company’s continued success in developing
therapies for patients where there is a large unmet medical
need.”
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical stage
biopharmaceutical company utilizing artificial intelligence
approaches to develop transformative medicines in neuroscience and
immuno-oncology. BioXcel’s drug re-innovation approach leverages
existing approved drugs and/or clinically validated product
candidates together with big data and proprietary machine learning
algorithms to identify new therapeutic indices. BioXcel’s two most
advanced clinical development programs are BXCL501, an
investigational, proprietary, orally dissolving thin film
formulation of dexmedetomidine for the treatment of agitation and
opioid withdrawal symptoms, and BXCL701, an investigational, orally
administered, systemic innate immunity activator in development for
the treatment of aggressive forms of prostate cancer and advanced
solid tumors that are refractory or treatment naïve to checkpoint
inhibitors. For more information, please visit
www.bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release include but are not limited to the Company's growth and
corporate strategy. When used herein, words including "anticipate,”
"being,” "will,” “look,” "plan,” "may,” "continue," and similar
expressions are intended to identify forward-looking statements. In
addition, any statements or information that refer to expectations,
beliefs, plans, projections, objectives, performance, or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon BioXcel's current expectations and
various assumptions. BioXcel believes there is a reasonable basis
for its expectations and beliefs, but they are inherently
uncertain.
BioXcel may not realize its expectations, and
its beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various important factors, including,
without limitation, its limited operating history; its incurrence
of significant losses; its need for substantial additional funding
and ability to raise capital when needed; its limited experience in
drug discovery and drug development; its dependence on the success
and commercialization of its product candidates; the failure of
preliminary data from its clinical studies to predict final study
results; failure of its early clinical studies or preclinical
studies to predict future clinical studies; its ability to receive
regulatory approval for its product candidates; its ability to
enroll patients in its clinical trials; undesirable side effects
caused by BioXcel's product candidates; its approach to the
discovery and development of product candidates based on EvolverAI
is novel and unproven; its exposure to patent infringement
lawsuits; its ability to comply with the extensive regulations
applicable to it; impacts from the COVID-19 pandemic; its ability
to commercialize its product candidates; and the other important
factors discussed under the caption "Risk Factors" in its Quarterly
Report on Form 10-Q for the quarterly period ended September 30,
2020, as such factors may be updated from time to time in its other
filings with the SEC, which are accessible on the SEC's website at
www.sec.gov and the Investors section of BioXcel’s website at
www.bioxceltherapeutics.com.
These and other important factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While BioXcel may elect to update
such forward-looking statements at some point in the future, except
as required by law, it disclaims any obligation to do so, even if
subsequent events cause our views to change. These forward-looking
statements should not be relied upon as representing BioXcel's
views as of any date subsequent to the date of this press
release.
Contact Information:
BioXcel Therapeutics,
Inc.www.bioxceltherapeutics.com
Investor Relations:
Mary ColemanBioXcel Therapeutics, V.P. of Investment
RelationsMColeman@bioxceltherapeutics.com1.475.238.6837
John GrazianoSolebury
Troutjgraziano@soleburytrout.com1.646.378.2942
Media:
Julia DeutschSolebury
Troutjdeutsch@soleburytrout.com1.646.378.2967
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Sep 2023 to Sep 2024